Posts Tagged ‘Medtech’
Gottlieb Brings VC Toolkit to FDA
Soon-to-be FDA commissioner, Scott Gottlieb, MD, is well positioned to understand where the medtech and biotech communities are coming from. He’s been a partner at the venture capital fund New Enterprise Associates since he left the FDA in 2007, where he served as deputy FDA commissioner under President George W. Bush, and performed a stint…
Read MoreAllergan Makes a Play in Gene Editing
With its licensing agreement to develop genome-editing programs with Editas Medicine to treat retinal diseases, Allergan has made a move to partner with one of the leading players in the CRISPR genome-editing space at a time when the field is poised to take off. That’s not Allergan’s hype. A recent report by San Francisco-based Grand…
Read MoreIs DR Just the Start for Google Brain?
A team of investigators recently reported online in the Journal of the American Medical Association1 that a Google algorithm allows computers to diagnose diabetic retinopathy (DR) using retina photos. The technology will never replace doctors, but Google hopes it will assist them, especially in underserved areas. Google’s first priority with this technology is to distribute…
Read MoreEncore Vision Delivers Big Payday to Angel Investors
Big winners in Novartis AG’s acquisition of Encore Vision for $465 million are members of a network of angel investors in Fort Worth, TX, that bet $4 million on the presbyopia-correcting eye drop that Encore Vision president and CEO Bill Burns has been working on for about nine years. The $4 million the Cowtown Angels…
Read MoreGoogle–Moorfields Venture Eyes AI to Speed Diagnosis with OCT
Google’s DeepMind Health artificial intelligence project and Moorfields Eye Hospital in London have teamed up for a five-year venture to develop an algorithm using one million anonymized retina scans from the Moorfields’ database to speed up and improve diagnosis of age-related macular degeneration (AMD) and diabetic retinopathy. Google and Moorfields announced the collaboration this month.…
Read MoreLudwin Monz, PhD, Discusses Zeiss, its Legacy & Where it Pursues New Innovation
Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec AG, shares how his company’s long history in ophthalmology helps it pave a path for new markets and technologies. Podcast Guest Ludwin Monz, PhD Dr. Ludwin Monz has been President and CEO of Carl Zeiss Meditec AG since 2010 and was appointed a member of…
Read MoreBausch + Lomb’s CMO Cal Roberts on How He Uses His MD & Experience to Build the Right Tool Kit for Ophthalmologists
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 088″] Bausch + Lomb’s chief medical officer Calvin Roberts, MD, still thinks like a doc when he’s helping to steer the company’s strategy. Hear how he sees B+L making life simpler for ophthalmologists in the near future. Podcast Guest Calvin W. Roberts, MD Calvin W. Roberts, MD, is Executive Vice President…
Read MoreZeiss CEO Monz on Building a Really Strong Brand
Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, shares how his company’s long history in ophthalmology helps it pave a path for new markets and technologies. Video Highlights 00:34 – How much of Carl Zeiss is ophthalmology? 01:00 – In ophthalmology we try to provide everything needed for diagnosis and treatment. 01:30…
Read MoreB&L’s Roberts Still Thinks Like a Doctor
Calvin Roberts, MD, CMO at Bausch & Lomb lends his physician’s perspective to how companies like Bausch & Lomb can serve eye care. Video Highlights 00:42 – I’m always asking what can we do for patient and what can we do for doctors? 01:00 – Think of all the things we do today for doctors…
Read MoreNew CEO Boorady Explains TearScience’s Strategic Shift
TearScience, the device company focused on the role of the meibomian glands in dry eye, has pivoted its business model to concentrate more on early-stage meibomian gland dysfunction (MGD) with the LipiFlow thermal pulsation device and high-definition imaging of the meibomian glands. Highlights 00:39 – When did you join TearScience and what changes did you…
Read MoreMynosys Eye Commercial Launch of Zepto
Zepto represents an “innovative, disposable capsulotomy device,” said president and CEO John Hendrick. It does not disrupt the natural flow of cataract procedures or patient flow. Its proprietary cutting edge doesn’t burn tissue (no cautery, thermal burning), but instead cleaves the tissue, providing an “unusual edge to the capsulotomy,” he explained. Finally, the device requires…
Read MoreFive Novel Innovations from WTF@OIS
The “What’s the Future@OIS” session at OIS@ASCRS 2016 showcased five novel innovations in ophthalmology that are difficult to place into any existing categories of ophthalmic devices and drugs. Here’s a quick look at them. Depressurizing goggles for glaucoma. Equinox is developing the Balance Goggles, which create a small vacuum on the eyes for people with…
Read More